Rocket Lab’s Pivotal Moment: Hypersonic Tests and Earnings Collide

Rocket Lab USA US7731221062

While Rocket Lab USA's share price has faced recent pressure, the company's operational tempo tells a different story. As the stock corrects from a significant rally, the aerospace firm is gearing up for its fourth hypersonic test mission in just six months. With quarterly earnings on the horizon, investors are watching to see if the company's expanding defense portfolio can reignite Wall Street's enthusiasm.

The immediate focus for Rocket Lab is a dual financial and operational milestone. After market close on February 26th, the company will release its fourth-quarter and full-year 2025 results. These figures are anticipated to provide concrete evidence of whether the firm's ambitious growth trajectory is being realized. This financial disclosure comes at a crucial juncture, bookended by a significant technical demonstration.

Shortly before the earnings report, attention will shift to Virginia's launch complex. Scheduled for late February, the "Cassowary Vex" mission will see Rocket Lab's HASTE rocket carry a scramjet vehicle developed by its Australian partner, Hypersonix for the Defense Innovation Unit (DIU). Internally dubbed "That's Not A Knife," this will mark the fourth such test conducted in under half a year.

Defense Segment Gains Strategic Weight

This repeated testing underscores Rocket Lab's specialized capabilities. The HASTE platform facilitates tests at velocities reaching Mach 20 and provides exacting control over flight profiles, cementing the company's role as a key partner for U.S. hypersonic development programs. The strategic importance of its defense business was further highlighted in December, when Rocket Lab secured an $816 million contract with the Space Development Agency to build missile-tracking satellites.

Share Price Volatility Meets Institutional Interest

Despite these operational strides, the equity has exhibited notable volatility. Following a powerful run early in the year that pushed shares to highs near $96, profit-taking and valuation concerns have since exerted downward pressure. Recent trading has seen the stock well below those peaks, with a trading range on February 17th between $65 and just under $71.

Interestingly, this price correction appears to have attracted some major institutional players. During the fourth quarter of 2025, investment managers Baillie Gifford and Vanguard each increased their holdings by more than 5 million shares, signaling a vote of long-term confidence even as the broader institutional ownership picture remains mixed.

The coming weeks will therefore be decisive, testing both Rocket Lab's technological execution and its financial fundamentals under the market's scrutiny.